Table 3.
Procedural details, medications and clinical outcomes for patients with ischaemic MR presenting with anterior and inferior STEMI
| Variable | Anterior STEMI | Inferior STEMI | p Value |
|---|---|---|---|
| Intervention | Plain old ballon angioplasty (POBA) 29.5% Bare metal stent (BMS) 49.7% Drug eluting stent (DES) 21.8% |
POBA 22% BMS 59.3% DES 18.2% |
0.02* |
| DBT: median (IQR) | 104 (37 184) | 106 (40 168) | 0.5 |
| Radial access | 0.3% | 0.3% | 0.8 |
| GP IIB/IIIA inhibitors | 67.8% | 72.3% | 0.2 |
| TIMI III result | 87.2% | 91.3% | 0.07 |
| Residual stenosis >90% | 6.7% | 5% | 0.4 |
| Blood transfusion | 24.2% | 20.1% | 0.2 |
| RP bleed | 1.3% | 0.4% | 0.2 |
| Haematoma | 5.7% | 3.8% | 0.2 |
| Pseudoaneurysm | 1.8% | 0.9% | 0.3 |
| AV fistula | 0.4% | 0.4% | 0.9 |
| Acute kidney injury | 10.1% | 8.9% | 0.6 |
| Emergency CABG | 2.7% | 3% | 0.8 |
| LOS (days): median (IQR) | 5.3 (3.3–10.2) | 4 (3–8.6) | 0.005* |
| Aspirin (ASA) at discharge | 97.5% | 98.2% | 0.3 |
| Statin at discharge | 88.2% | 87.6% | 0.4 |
| β-blocker at discharge | 79.5% | 78.8% | 0.7 |
| ACE inhibitors at discharge | 71.2% | 68% | 0.1 |
| 30-day mortality | 14.9% | 6.8% | 0.001* |
| 1-year mortality | 26.4% | 14.3% | <0.0001* |
| 3-year mortality | 39.7% | 24.8% | <0.0001* |
*values have reached statistical significance
ASA, Aspirin; AV, arteriovenous; BMS, Bare metal stent; CABG, coronary artery bypass graft; DBT, door-to-balloon time; DES, Drug eluting stent; GP, glycoprotein; LOS, length of hospital stay; MR, mitral regurgitation; POBA, Plain old ballon angioplasty; RP, retroperitoneal; STEMI, ST elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.